The tumour necrosis factor (TNF)-α system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus

European Journal of Endocrinology

Volumn 153, Issue 5, 2005, Pages 687-691

  Gonzalez Clemente J M ^b   Gimenez Perez G ^b   Richart, C ^a   Broch, M ^a   Caixas A ^b   Megia, A ^a   Gimenez Palop O ^b   Simon I ^a   Mauricio, D ^b   Vendrell, J ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGE; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; FEMALE; GENDER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROANGIOPATHY; PRIORITY JOURNAL; PULSE PRESSURE; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFLAMMATION; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYSTOLE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27944487111     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02016     Document Type: Article

References (36)

1. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z & Keen H. The British Diabetic Association Cohort Study. II. Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabetic Medicine 1999 16 466-471.
2. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EA, Patterson CC, Qiao Z & Keen H. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 2003 34 418-421.
3. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ & Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. New England Journal of Medicine 2004 351 2599-2610.
4. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH & Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 2005.
5. Dart AM & Kingwell BA. Pulse pressure - a review of mechanisms and clinical relevance. Journal of the American College of Cardiology 2001 37 975-984.
6. Domanski M, Norman J, Wolz M, Mitchell G & Pfeffer M. Cardiovascular risk assessment using pulse pressure in the first National Health and Nutrition Examination Survey (NHANES I). Hypertension 2001 38 793-797.
7. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB & Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 103 1245-1249.
8. Benetos A, Rudnichi A, Safar M & Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998 32 560-564.
9. Ronnback M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A & Groop PH. Altered age-related blood pressure pattern in type 1 diabetes. Circulation 2004 110 1076-1082.
10. Schram MT, Chaturvedi N, Fuller JH & Stehouwer CD. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. Journal of Hypertension 2003 21 2035-2044.
11. Berry KL, Skyrme-Jones RA, Cameron JD, O'Brien RC & Meredith IT. Systemic arterial compliance is reduced in young patients with IDDM. American Journal of Physiology 1999 276 H1839-H1845.
12. Romney JS & Lewanczuk RZ. Vascular compliance is reduced in the early stages of type 1 diabetes. Diabetes Care 2001 24 2102-2106.
13. Ryan SM, Waack BJ, Weno BL & Heistad DD. Increases in pulse pressure impair acetylcholine-induced vascular relaxation. American Journal of Physiology 1995 268 H359-H363.
14. Hensley K, Robinson KA, Gabbita SP, Salsman S & Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radical Biology and Medicine 2000 28 1456-1462.
15. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004 44 248-252.
16. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD & Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. Journal of the American College of Cardiology 2004 44 1819-1824.
17. Schulze MB, Shai I, Rimm EB, Li T, Rifai N & Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005 54 534-539.
18. Goday A, Castell C, Tresserras R, Canela J, Taberner JL & Lloveras G. Incidence of type 1 (insulin-dependent) diabetes mellitus in Catalonia, Spain. The Catalan Epidemiology Diabetes Study Group. Diabetologia 1992 35 267-271.
19. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotem cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
20. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW & Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). American Journal of Kidney Diseases 2003 42 617-622.
21. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N & Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994 17 1281-1289.
22. Perkins BA, Olaleye D, Zinman B & Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001 24 250-256.
23. Vinik AI, Maser RE, Mitchell BD & Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003 26 1553-1579.
24. Vespasiani G, Bruni M, Meloncelli I, Clementi L, Amoretti R, Branca S, Carinci F, Lostia S, Nicolucci A, Romagnoli F, Verga S & Benedetti MM. Validation of a computerised measurement system for guided routine evaluation of cardiovascular autonomic neuropathy. Computer Methods and Programs in Biomedicine 1996 51 211-216.
25. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H & Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. European Journal of Haematology 1995 54 1-8.
26. Benjafield AV, Wang XL & Morris BJ. Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease. Journal of Molecular Medicine 2001 79 109-115.
27. Van Greevenbroek MM, Van Der Kallen CJ, Geurts JM, Janssen RG, Buurman WA & De Bruin TW. Soluble receptors for tumor necrosis factor-alpha (TNF-R p55 and TNF-R p75) in familial combined hyperlipidemia. Atherosclerosis 2000 153 1-8.
28. Mitchell GF & Pfeffer MA. Pulsatile hemodynamics in hypertension. Current Opinion in Cardiology 1999 14 361-369.
29. Chappell DC, Varner SE, Nerem RM, Medford RM & Alexander RW. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circulation Research 1998 82 532-539.
30. Baumann H & Gauldie J. The acute phase response. Immunology Today 1994 15 74-80.
31. Abramson JL, Weintraub WS & Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002 39 197-202.
32. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB & Pahor M. inflammatory markers and cardiovascular disease (the Health Aging and Body Composition [Health ABC] Study). American Journal of Cardiology 2003 92 522-528.
33. Fernandez-Real JM & Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003 24 278-301.
34. Fernandez-Real JM, Gutierrez C, Ricart W, Castineira MJ, Vendrell J & Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis 1999 146 321-327.
35. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS & Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. PNAS 1999 96 6902-6907.
36. Avolio A. Pulse pressure and inflammatory markers. Journal of Hypertension 2004 22 247-249.